Opzelura (ruxolitinib cream) / Incyte, Maruho, China Medical System - LARVOL DELTA

New topical molecular targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis. (PubMed, Pediatr Allergy Immunol) - "Nine studies (reported in eight articles) involving 2182 patients were included, with 1469 children treated with Janus kinase inhibitors (ruxolitinib and delgocitinib) and phosphodiesterase-4 inhibitors (crisaborole, lotamilast, and difamilast)...New topical targeted therapies administered over 4 weeks are effective and safe for children with atopic dermatitis aged ≤18 years. Further studies are needed to establish their long-term safety and efficacy."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dermatologic adverse events in patients receiving duvelisib single-agent and combination therapies (SID 2025) - "We noted a lower incidence of DAEs (p=.004) and fewer patients with severe DAEs (p=.04), trending towards shorter duration DAE (p=.08), in patients on duvelisib in combination with romidepsin, bortezomib or ruxolitinib compared to patients on duvelisib alone. Further studies are required to delineate the effects of other agents on incidence and severity of PI3Ki-associated DAEs."

Adverse events • Clinical • Combination therapy • Hematological Malignancies • Leukemia • Lymphoma • Mucositis • Oncology • T Cell Non-Hodgkin Lymphoma

RAD 2025 Poster Highlights Ruxolitinib Cream Safety in Combination AD Regimens (DermatologyTimes) - "A recent multi-center retrospective study, presented as a poster at the 2025 Revolutionizing Atopic Dermatitis (RAD) meeting in Nashville, Tennessee, aimed to assess the real-world safety and clinical outcomes of long-term RUX 1.5% cream when integrated with systemic therapies for AD. Analyzing data from 115 AD patients, researchers observed that the vast majority experienced no treatment-related adverse events (AEs), and those reported were notably mild and infrequent.....Efficacy outcomes at week 52 were compelling, demonstrating substantial improvements across key clinical measures. In cohort A, mean changes from baseline were impressive: IGA -2.57 ± 0.54, BSA -8.03 ± 2.17, and itch score -8.04 ± 0.37. Cohort B similarly showed robust improvements with mean changes of IGA -2.38 ± 0.54, BSA -22.62 ± 4.94, and itch score -6.18 ± 0.27. These efficacy data underscore the real-world clinical benefit achievable with this combination approach."

Retrospective data • Atopic Dermatitis

Wells syndrome: emerging triggers and treatments- an updated systematic review. (PubMed, Arch Dermatol Res) - "Recent literature expands the clinical spectrum of Wells syndrome, highlighting new immunologic and iatrogenic triggers. Targeted treatments, especially biologics and Janus kinase inhibitors, demonstrate promising results and may offer steroid-sparing alternatives for patients with refractory disease. Clinicians should consider emerging triggers in differential diagnosis and evaluate newer therapies in recurrent or treatment-resistant cases. Further prospective and registry-based studies are warranted to validate efficacy and support development of evidence-based management guidelines."

Journal • Review • Dermatology • Infectious Disease • Influenza • Novel Coronavirus Disease • Oncology • Pediatrics • Respiratory Diseases

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (clinicaltrials.gov) - P3 | N=450 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology

Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis (EADV-Sp 2025) - "This study suggests that topical ruxolitinib (1.5%, twice daily) is more effective than roflumilast (0.15%, once daily) in achieving TS and EASI-75 in patients with mild-to-moderate AD. Nonetheless, treatment decisions should be individualized and consider differences in mechanism, dosing, and safety profiles. Further studies with comparisons to established therapies (i.e."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology

TRuE-AD5: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=240 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Treatment with topical Ruxolitinib is associated with reduced Staphylococcus aureus burden in chronic hand dermatitis (SID 2025) - P1/2 | "This study highlights the promising role of RUX in CHD management, with clinical improvement associated to reduced Sa burden and a reversed trend after stopping RUX. Further studies are needed to investigate the contribution of Sa burden in CHD as well as the direct or indirect (e.g. inflammatory mediated) mechanism of RUX."

Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Treatment options for refractory chilblain lupus (SID 2025) - "For JAK inhibitors, 1 patient experienced transient thrombocytopenia that resolved with ruxolitinib holiday and did not recur upon reinitiation. The most promising treatments in this review were JAK inhibitors, given their similar efficacy and a more favorable safety profile than antimalarials."

Late-breaking abstract • Cutaneous Lupus Erythematosus • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Thrombocytopenia

A randomized interventional study that compares treatments for vitiligo and anti-vitiligo cream. (PubMed, Eur J Transl Myol) - "Participants were divided into five groups (200 patients each): oral prednisolone, Tofacitinib, Ruxolitinib, AVC (Anti-Vitiligo Cream), and AVC combined with Tofacitinib...AVC (Anti-Vitiligo Cream), particularly in combination with Tofacitinib, represents a groundbreaking approach for managing vitiligo, providing enhanced efficacy and patient satisfaction. These findings support the potential of AVC-based therapies as a standard treatment option."

Journal • Dermatology • Immunology • Vitiligo

Segmental Vitiligo: Rapid Spread From a Halo Nevus. (PubMed, Cureus) - "Recent guidelines suggest first-line use of topical calcineurin inhibitors like tacrolimus or JAK/STAT inhibitors like ruxolitinib. Understanding diverse vitiligo presentations is crucial for more precise diagnosis and treatment strategies."

Journal • Dermatology • Immunology • Pediatrics • Vitiligo

Natural product-based compounds demonstrate potent anti-inflammatory and anti-itch effects in a mouse model of atopic dermatitis (SID 2025) - "In a MC903-induced mouse model of AD, DB007-5 demonstrated strong and concentration dependent inhibition of inflammation score (p<0.05 for 0.5%, 0.75% and 1% concentrations). Further, at 0.75%, DB007-5 reduced scratching (itch) score at Day 12 from 7.2+/-2.70 in vehicle treated group to 0.70+/-0.33, p<0.05), while ruxolitinib 1.5% reduced the scratching score to 1.7+/-0.62, p<0.05). In summary, DB007-5 demonstrated strong anti-inflammatory effects as well as potent inhibition of the primary symptom of AD, namely itch. Further studies are underway to evaluate the potential of DB007-5 as a therapy for AD."

Late-breaking abstract • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4 • IL5

TRuE-AD4: A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=241 | Active, not recruiting | Sponsor: Incyte Corporation | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Topical ruxolitinib 1.5% cream improves immune and barrier dysregulation in patients with moderate-to-severe seborrheic dermatitis (SID 2025) - "These results demonstrate meaningful normalization of the transcriptome in patients with moderate-to-severe SD, supporting the addition of ruxolitinib to the treatment armamentarium. The observed improvement identifies a strafication of complete responders in 4 weeks, suggesting a molecular propensity for treatment response to be further investigated."

Clinical • Dermatitis • Dermatology • Immunology • Inflammation • Seborrheic Dermatitis • CLDN1 • IL17A • IL1B • IL22 • IL23A • MX1 • OASL • STAT1 • STAT3

3D imaging elucidates neuroimmune dynamics in atopic dermatitis skin treated with ruxolitinib cream (SID 2025) - "This reinforces the observation that AD lesional and nonlesional skin share similar nerve volume characteristics. By leveraging cutting-edge 3D imaging and machine learning, this study introduces an innovative framework for understanding skin diseases."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • PTPRC

A novel humanized mouse model closely mimics human vitiligo (SID 2025) - "Tacrolimus and Opzelura effectively promoted repigmentation in experimentally induced vitiligo lesions, achieving 30% and 70% repigmentation, respectively. In this preclinical model, vitiligo pathogenesis can be interrogated and candidate vitiligo therapeutics tested under clinically relevant conditions in vivo."

Preclinical • Dermatology • Immunology • Vitiligo • CAT • CD8 • CDKN2A • IFNA1 • IFNG • IL15 • IL18 • ITGAX • KIT • KRT10 • NKG2D • SIRT1 • Tyrosinase

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Incyte Corporation | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Prurigo Nodularis

Complete Resolution of Granulomatous Rosacea With Topical Ruxolitinib. (PubMed, Cureus) - "After failing multiple established treatments, the patient achieved near-complete resolution of her condition following 10 months of combination therapy with topical ruxolitinib and metronidazole cream. This case highlights the potential efficacy of topical JAK inhibitors as a novel therapeutic approach for recalcitrant GR."

Journal • Dermatology • Inflammation • Rosacea

Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Incyte Corporation | Trial completion date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Apr 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Immunology • Prurigo Nodularis

Topical ruxolitinib for treatment of mycosis fungoides and lymphomatoid papulosis. (PubMed, Br J Dermatol) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology

Disseminated Varicella-Zoster Virus-Associated Acute Retinal Necrosis in a Post-Bone Marrow Transplant Patient. (PubMed, Ocul Immunol Inflamm) - "A 45-year-old male with aplastic anaemia who underwent a bone marrow transplantation developed GVHD and was treated with ruxolitinib and tacrolimus...The patient's right eye symptoms were resolved with topical acyclovir and supportive care, achieving a best-corrected visual acuity of 6/6...Our case highlights the disseminated and asymmetric nature of herpes zoster infection in the context of severe immunosuppression. This emphasizes the need to balance effective GVHD treatment and reinforces the importance of ongoing vigilance and timely management of these high-risk individuals."

Journal • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Retinal Disorders • Transplantation • Varicella Zoster

Management of vitiligo: a promising future. (PubMed, Ital J Dermatol Venerol) - "Topical corticosteroids (TCS), calcineurin inhibitors, and novel agents like ruxolitinib have shown efficacy in managing localized vitiligo, with oral JAK inhibitors emerging as promising treatments for more extensive disease...However, challenges remain in achieving sustained repigmentation and preventing relapse. Future research should focus on optimizing combination therapies and exploring novel biologic agents to improve long-term outcomes."

Journal • Dermatology • Immunology • Transplantation • Vitiligo

COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Janssen Research & Development, LLC | Active, not recruiting ➔ Recruiting | N=201 ➔ 300

Adverse events • Enrollment change • Enrollment open • Dermatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR